- Modulation of allergic and non-allergic airway inflammation
- Immune-regulation of lipid mediator pathways
Allergic diseases are caused by excessive type 2 immune responses towards harmless antigens. In addition to typical allergies, chronic inflammatory diseases with allergy-like symptoms affect an ever-increasing number of patients. Both nature and pharmaceutical inventions have produced modulators that can selectively direct immune responses. The mission of the group is to explore such immunomodulators to support allergy and asthma therapy.
Pro-inflammatory lipid mediators (leukotrienes) are central, but yet understudied players in the pathogenesis of asthma and nose polyps. However, current therapies fail to sufficiently target the leukotriene pathway. Thus, a particular focus of our work is to identify immunomodulatory molecules, which impact on leukotriene-driven airway inflammation.
Julia Esser-von Bieren, PhD
Zentrum Allergie und Umwelt (ZAUM)
Technische Universität und Helmholtz Zentrum München
Biedersteiner Str. 29
Phone: +49 89 4140-3464